Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.70 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.62 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.62 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9065025 | 1.00 | KYNU (0.70) | KYNUGRM2GRM3SLC1A2SLC1A1 | |
| SCHEMBL9064883 | 1.00 | KYNU (0.70) | KYNUGRM2GRM3SLC1A2SLC1A1 | |
| SCHEMBL9065063 | 1.00 | KYNU (0.70) | KYNUGRM2GRM3SLC1A2SLC1A1 | |
| SCHEMBL5282418 | 0.83 | GRM2 (0.79) | KYNUGRM2GRM3SLC1A2SLC1A1 | |
| SCHEMBL23265574 | 0.83 | KYNU (0.55) | KYNUGRM2GRM3SLC1A2SLC1A1 | |
| SCHEMBL617705 | 0.83 | KYNU (1.00) | KYNUGRM2GRM3LMNA | |
| SCHEMBL5286288 | 0.80 | GRM2 (0.62) | KYNUGRM2GRM3SLC1A2SLC1A1 | |
| SCHEMBL6448129 | 0.80 | GRM2 (0.62) | KYNUGRM2GRM3SLC1A2SLC1A1 | |
| SCHEMBL27564208 | 0.79 | LMNA (0.52) | KYNUBCAT2LMNAMAPK1AOC3 | |
| SCHEMBL27564209 | 0.79 | LMNA (0.52) | KYNUBCAT2LMNAMAPK1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0581907-A4 | — | — | 1994-04-06 | — | — | EP | claimed |
| EP-0581907-A1 | INHIBITORS OF KYNURENINASE | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1994-02-09 | — | — | EP | claimed |
| WO-1992018003-A1 | INHIBITORS OF KYNURENINASE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-10-29 | — | — | WO | claimed |
| CN-115784916-A | Method for preparing 2- (S) -amino-4-aryl butyric acid compound | 杭州励德生物科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| CN-101252926-A | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | INNODIA INC (CA) | 2008-08-27 | — | — | CN | disclosed |
| CN-101193852-A | 4-Hydroxyisoleucine analogs and uses thereof | INNODIA INC (CA) | 2008-06-04 | — | — | CN | disclosed |
| EP-1874287-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF OBESITY AND RELATED SYNDROMES | Innodia Inc. (CA) | 2008-01-09 | — | — | EP | disclosed |
| EP-1858840-A2 | ANALOGS OF 4-HYDROXYISOLEUCINE AND USES THEREOF | Innodia Inc. (CA) | 2007-11-28 | — | — | EP | disclosed |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | UNIVERSITE LOUIS PASTEUR STRASBOURG I (FR) | 2006-09-07 | — | — | US | disclosed |
| US-5516936-A | TREATMENT OF NEUROLOGICAL DISORDERS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-05-14 | — | — | US | disclosed |
| US-5495044-A | Inhibitors of kynureninase | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5442104-A | Neurological disorders | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1995-08-15 | — | — | US | disclosed |
| WO-1995011878-A1 | INHIBITORS OF KYNURENINASE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| EP-0581907-A4 | — | — | 1994-04-06 | — | — | EP | disclosed |
| EP-0581907-A1 | INHIBITORS OF KYNURENINASE | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1994-02-09 | — | — | EP | disclosed |
| US-5254725-A | Inhibitors of kynureninase | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1993-10-19 | — | — | US | disclosed |
| WO-1992018003-A1 | INHIBITORS OF KYNURENINASE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | GPR119, SLC2A1, SLC5A1 | KYNU 770/4885GRM2 776/4885GRM3 1784/4885 |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | LIPC, PC, LIPE | KYNU 192/4885GRM2 1702/4885GRM3 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.